Competition Law and Synthetic Biology Market Concentration

1. Introduction

Synthetic biology combines biology, genetic engineering, automation, computational design, DNA synthesis, genome editing, sequencing, fermentation and biological manufacturing to create or modify organisms and biological systems for commercial purposes.

From a competition-law perspective, synthetic biology can produce highly concentrated markets because successful firms may control scarce and difficult-to-replicate assets such as:

• proprietary DNA and genetic sequences;
• DNA synthesis and sequencing platforms;
• CRISPR and other genome-editing technologies;
• engineered microorganisms and cell lines;
• biological databases and genomic datasets;
• automated laboratory and biofoundry infrastructure;
• fermentation and biomanufacturing capacity;
• patents and know-how;
• specialized research tools;
• distribution and regulatory capabilities.

The central competition-law problem is therefore not merely whether one company has a large market share. It is whether concentration gives a firm the ability and incentive to restrict rivals' access to essential technologies, inputs, data, intellectual property or innovation pathways.

Importantly, there are relatively few reported cases concerning synthetic biology as a legally defined market. Consequently, the most useful precedents come from closely related markets—DNA sequencing, biotechnology, pharmaceuticals, agricultural biotechnology, seeds and biological innovation. The following cases illustrate the principles most applicable to synthetic-biology concentration.

2. Why Synthetic Biology Markets Can Become Highly Concentrated

Synthetic biology has several structural characteristics that can facilitate concentration.

A. High R&D costs

Developing a commercially viable biological platform can require:

• laboratories;
• high-throughput screening;
• genomic databases;
• computational infrastructure;
• specialized scientists;
• regulatory approval;
• manufacturing facilities.

A small number of successful firms can therefore accumulate substantial advantages.

B. Intellectual-property accumulation

A synthetic-biology company may possess large patent portfolios covering:

• genetic constructs;
• biological pathways;
• enzymes;
• microorganisms;
• manufacturing processes;
• gene-editing techniques;
• diagnostic applications.

A dense patent portfolio may create barriers to entry even where the underlying scientific technology is theoretically reproducible.

C. Network effects and data advantages

AI-assisted biology increasingly depends on datasets generated from:

• sequencing;
• protein structures;
• experimental results;
• biological assays;
• failed experiments;
• fermentation performance.

More users can produce more data, which can improve the platform and attract additional users.

This can create a data-feedback loop:

More users → more experiments → more data → better models → more users → greater market power.

D. Vertical integration

A company may control several stages:

DNA design → DNA synthesis → sequencing → biological testing → software → manufacturing → distribution.

Vertical integration may produce efficiencies, but it can also create foreclosure risks.

E. Nascent competition

Synthetic-biology markets often develop around technologies that have not yet reached commercial maturity.

Consequently, a small start-up may not have substantial current sales but may nevertheless represent an important future competitive constraint.

This is particularly important under modern merger control.

3. Relevant Competition-Law Framework

Synthetic-biology concentration can be examined through several areas of competition law.

A. Merger control

Competition authorities may examine:

• horizontal mergers;
• vertical mergers;
• conglomerate mergers;
• acquisitions of start-ups;
• acquisitions of potential competitors;
• acquisitions of innovation pipelines.

The principal question is whether the transaction may substantially lessen or impede competition.

B. Abuse of dominance

A dominant synthetic-biology platform could potentially engage in:

• refusal to supply;
• discriminatory access;
• exclusive licensing;
• tying;
• bundling;
• discriminatory pricing;
• self-preferencing;
• exclusionary rebates;
• predatory pricing;
• excessive contractual restrictions.

C. Intellectual-property abuse

Patent ownership itself is generally not unlawful.

However, competition concerns may arise where intellectual-property rights are used as instruments of exclusion, particularly through:

• strategic patent accumulation;
• sham litigation;
• exclusionary licensing;
• discriminatory licensing;
• refusal to license under exceptional circumstances;
• patent settlements designed to delay competition.

D. Essential-facility/access issues

Some synthetic-biology infrastructure may become difficult or impossible for rivals to reproduce economically.

Examples could include:

• unique sequencing infrastructure;
• specialized biological databases;
• scarce high-throughput screening capacity;
• specialized biofoundries;
• unique biological manufacturing facilities.

A refusal to provide access may become competition-sensitive where the legal requirements for an access obligation are satisfied.

4. Case Law

Case 1 — Illumina, Inc. / Pacific Biosciences of California

United States — FTC, 2019–2020

This is one of the most directly relevant precedents for synthetic biology.

Illumina proposed acquiring Pacific Biosciences, a competitor in next-generation DNA sequencing. The FTC alleged that Illumina was already the leading supplier of next-generation sequencing systems and that PacBio represented a nascent competitive threat.

The FTC alleged that eliminating PacBio would reduce both existing and future competition and weaken incentives to innovate. The parties ultimately abandoned the transaction.

Relevance to synthetic biology

Sequencing is foundational infrastructure for synthetic biology.

The case demonstrates that competition authorities may look beyond current market shares and ask:

Could the target become an important technological competitor in the future?

This is particularly significant when a dominant platform seeks to acquire a smaller technological challenger.

Principle

Nascent competition can constitute an important competitive constraint even before the challenger reaches full commercial maturity.

5. Case 2 — Illumina, Inc. / GRAIL, Inc.

United States — FTC / Fifth Circuit, 2021–2023

Illumina's acquisition of GRAIL concerned cancer-detection tests based on DNA sequencing.

The FTC was concerned that Illumina controlled a critical input—next-generation sequencing technology—while GRAIL operated downstream in multi-cancer early detection.

The Commission ultimately ordered divestiture, concluding that the transaction could reduce competition and innovation. The Fifth Circuit found substantial evidence supporting the Commission's determination that the acquisition threatened competition, and Illumina subsequently announced that it would divest GRAIL.

Competition issue

This case illustrates vertical foreclosure.

The upstream firm could potentially have an incentive to:

• increase rivals' costs;
• restrict supply;
• degrade service;
• limit access to new technology;
• favor its downstream affiliate.

The FTC specifically identified sequencing platforms as a critical input for competing MCED developers.

Synthetic-biology significance

A similar structure could arise where:

Synthetic-biology platform → controls critical biological input → acquires downstream application company.

For example, competition authorities could examine whether control of:

• DNA synthesis,
• genome editing,
• sequencing,
• biological databases,
• laboratory automation,

could be used to disadvantage competing applications.

Principle

Vertical integration involving a critical technological input can create competition concerns even when the merging companies do not directly compete at the same level.

6. Case 3 — Genzyme / Novazyme

United States — FTC/DOJ competition analysis

Genzyme's acquisition of Novazyme became an important historical example in the development of innovation-market analysis.

Both firms were involved in research concerning enzyme replacement therapy for Pompe disease. The competition analysis considered whether the merger would eliminate an important research rivalry and potentially affect the race to develop a new therapy.

The DOJ's subsequent discussion of the case highlighted the difficulty of assessing competition where firms compete principally through R&D rather than established products.

Synthetic-biology relevance

Synthetic biology frequently involves firms competing through:

• research programs;
• laboratory platforms;
• experimental biological pathways;
• pipeline organisms;
• genetic engineering methods.

A start-up therefore may be competitively important even if it has:

• no significant sales;
• no approved product;
• no established customer base.

Principle

Competition may occur at the level of innovation and R&D before a conventional product market has fully developed.

This is particularly important for synthetic-biology acquisitions.

7. Case 4 — Bayer / Monsanto

European Union — European Commission, 2018

The Bayer/Monsanto transaction is highly relevant to synthetic biology because it involved seeds, genetic traits, crop protection and agricultural biotechnology.

The European Commission identified competition concerns involving overlapping seed and pesticide activities and required extensive divestitures. The remedies included Bayer's global R&D organization for seeds and traits and other research assets. The Commission also required licensing relating to digital agriculture.

The Commission's assessment specifically considered the importance of innovation in crop protection and genetically engineered agricultural systems.

Competition concerns

The case illustrates several issues relevant to synthetic biology:

1. concentration of biological innovation;
2. control of genetic traits;
3. control of R&D pipelines;
4. portfolio effects;
5. access to biological technologies;
6. elimination of innovation competitors.

Principle

Merger control can protect future biological innovation, not merely existing product-market competition.

8. Case 5 — Dow / DuPont

European Union — European Commission, 2017

The Dow/DuPont merger involved major agricultural and chemical businesses, including crop-protection products, seeds and R&D.

The Commission examined the effect of the merger on innovation, particularly because agricultural technology depends heavily on continuous development of new active ingredients and biological/agricultural technologies.

The Commission's later policy analysis identifies Dow/DuPont as an example in which innovation competition was important because environmental and biological changes can reduce the effectiveness of existing products.

Synthetic-biology relevance

Synthetic biology similarly involves innovation races.

A company may not currently dominate an established product market but may control an important pipeline of:

• engineered organisms;
• enzymes;
• biological production systems;
• alternative biological pathways.

If a merger removes one of only a few significant R&D programs, concentration can affect competition even without a dramatic immediate increase in market share.

Principle

Innovation competition is an independent dimension of competition that can justify merger intervention.

9. Case 6 — ChemChina / Syngenta

European Union — European Commission, 2017

The ChemChina/Syngenta transaction involved a major global agricultural biotechnology and crop-protection combination.

The case is important because the Commission assessed the transaction against an industry that was already experiencing substantial consolidation.

The subsequent Bayer/Monsanto assessment expressly took account of the competitive situation resulting from the earlier Dow/DuPont and ChemChina/Syngenta transactions.

Synthetic-biology relevance

This demonstrates the cumulative-concentration problem.

A merger cannot always be analysed in isolation.

Suppose an industry has:

10 competitors → Merger A → 7 competitors → Merger B → 5 competitors → Merger C → 3 competitors.

The third merger may produce significantly greater competitive risks than the first even if the immediate transaction appears similar.

Principle

Competition authorities may consider the cumulative effect of successive consolidation transactions in innovation-intensive biological industries.

10. Case 7 — Bristol-Myers Squibb / Celgene

United States — FTC, 2019–2021

Bristol-Myers Squibb proposed acquiring Celgene in a transaction valued at approximately $74 billion.

The FTC concluded that the transaction threatened competition in the market for oral treatments for moderate-to-severe psoriasis and required divestiture of Celgene's Otezla business. The divestiture included regulatory approvals, intellectual property, contracts and inventory.

Relevance to synthetic biology

The significance is not that psoriasis drugs are synthetic biology.

Rather, the case demonstrates the importance of preserving a complete competitive business, including:

• IP;
• regulatory approvals;
• contracts;
• products;
• manufacturing capabilities.

Synthetic-biology markets can similarly require remedies that transfer an entire technological platform rather than merely licensing a single patent.

Principle

An effective merger remedy may need to transfer the assets necessary to recreate an independent competitive constraint.

11. Case 8 — Mylan Pharmaceuticals v. Celgene

United States

This litigation concerned access to pharmaceutical samples needed by a potential generic competitor.

The FTC argued that a branded pharmaceutical company's refusal to provide samples could constitute exclusionary conduct under established antitrust principles, while emphasizing that patents do not automatically immunize all related conduct from antitrust scrutiny.

Synthetic-biology relevance

The analogous question could arise where a dominant biological platform controls access to:

• biological samples;
• testing materials;
• specialized datasets;
• reference organisms;
• proprietary reagents;
• critical experimental inputs.

The existence of IP rights does not automatically resolve the competition question.

Principle

Control over an indispensable input can become an antitrust issue where access restrictions exclude competing innovation.

12. Market-Concentration Issues Specific to Synthetic Biology

A. DNA synthesis concentration

A small number of firms controlling large portions of DNA synthesis could potentially create:

• supply dependence;
• discriminatory access;
• preferential treatment;
• higher switching costs;
• exclusion of smaller researchers.

Competition authorities should examine whether customers have realistic alternatives.

B. Genome-editing concentration

A firm with important CRISPR or related technology patents may obtain substantial market power through licensing.

Competition analysis should distinguish:

Patent exclusivity ≠ automatically unlawful monopoly.

The relevant question is whether the firm uses that position to unlawfully exclude competing technologies or markets.

C. Sequencing concentration

Sequencing platforms can constitute upstream infrastructure for:

• synthetic biology;
• precision medicine;
• diagnostics;
• agricultural biotechnology;
• genomic research.

The Illumina/PacBio and Illumina/GRAIL cases demonstrate why concentration at this level can be especially important.

13. Data Concentration

Synthetic biology is increasingly data-intensive.

A dominant firm could potentially possess:

Genomic data + experimental data + AI models + laboratory automation + proprietary databases.

This creates a possible data-driven competitive advantage.

Competition authorities may therefore need to examine:

• data portability;
• interoperability;
• access to scientific datasets;
• exclusive data arrangements;
• discriminatory API access;
• acquisition of data-rich start-ups.

The relevant question is whether control over data creates a durable barrier to entry.

14. Vertical Foreclosure

A synthetic-biology company may operate simultaneously as:

Platform provider → laboratory supplier → sequencing provider → software provider → biological manufacturer.

This can create foreclosure opportunities.

For example:

A dominant DNA-design platform acquires a DNA-synthesis company.

The merged entity might theoretically have an incentive to:

• increase rivals' synthesis prices;
• reduce turnaround times for its own customers;
• degrade competitors' access;
• bundle design software with synthesis;
• restrict interoperability.

The competition authority would examine both ability and incentive to foreclose, rather than assuming that vertical integration is automatically harmful.

15. Conglomerate Effects

Synthetic-biology firms often operate across several adjacent markets.

For example:

AI biology platform + DNA synthesis + sequencing + laboratory automation + cloud computing.

Bundling these products could potentially make it difficult for smaller competitors to compete.

Possible theories include:

• tying;
• bundling;
• loyalty discounts;
• portfolio effects;
• cross-subsidisation;
• interoperability restrictions.

16. Acquisition of Start-Ups

One of the most important synthetic-biology competition concerns is the acquisition of nascent firms.

A dominant company may acquire a start-up before the start-up becomes a serious competitor.

The relevant question is therefore not simply:

"Does the target currently have substantial revenue?"

Instead:

"What competitive constraint would the target probably have provided absent the acquisition?"

The Illumina/PacBio case provides an important illustration of this concern.

17. Innovation Competition

Synthetic biology requires continuous innovation.

Competition therefore occurs through:

• better biological pathways;
• lower-cost DNA synthesis;
• higher-throughput screening;
• more accurate sequencing;
• improved gene editing;
• faster biological design;
• more efficient fermentation;
• lower-cost biomanufacturing.

A merger that eliminates one of only two or three serious research programs may reduce competition even where conventional market-share analysis appears less alarming.

The Genzyme/Novazyme, Illumina/PacBio, Dow/DuPont and Bayer/Monsanto matters are particularly instructive on this point.

18. HHI and Market-Share Analysis

Traditional concentration analysis remains relevant.

The authority may examine:

• market shares;
• HHI;
• increment in concentration;
• number of competitors;
• barriers to entry;
• buyer power.

However, synthetic biology creates an important limitation.

Example

Suppose:

A conventional analysis might focus on these shares.

But suppose Firm D owns the only credible next-generation genome-editing technology.

Its innovation significance may be considerably greater than its current revenue share suggests.

Therefore:

Market share ≠ complete measure of competitive importance.

19. Entry Barriers

Synthetic-biology markets may have unusually high entry barriers.

Financial barriers

• expensive laboratories;
• high-throughput equipment;
• manufacturing facilities.

Scientific barriers

• specialist expertise;
• accumulated know-how;
• experimental datasets.

Regulatory barriers

• biosafety;
• pharmaceutical approvals;
• agricultural approvals.

Intellectual-property barriers

• patent thickets;
• exclusive licences;
• proprietary biological materials.

Data barriers

• proprietary datasets;
• trained AI models;
• experimental databases.

20. Competition Concerns in Synthetic Biology

The principal concerns can be summarized as follows:

21. Possible Competition-Law Remedies

Where concentration creates significant competitive concerns, authorities may consider:

Structural remedies

• divestiture of a business;
• divestiture of patents;
• transfer of biological platforms;
• sale of manufacturing facilities;
• transfer of research programs.

Behavioural remedies

• non-discrimination obligations;
• access commitments;
• licensing obligations;
• interoperability requirements;
• data-access commitments.

Innovation remedies

• continuation of R&D programs;
• preservation of independent research teams;
• licensing of competing technologies;
• restrictions on discontinuing pipeline projects.

The Bayer/Monsanto case demonstrates the importance of transferring R&D capabilities, while BMS/Celgene illustrates a remedy involving products, IP, regulatory approvals and related assets.

22. Application to India

Under the Competition Act, 2002, synthetic-biology concentration could potentially engage:

• Section 3 — anti-competitive agreements;
• Section 4 — abuse of dominant position;
• Sections 5 and 6 — combinations;
• CCI merger review;
• relevant-market definition;
• denial of market access;
• discriminatory conditions;
• tying and bundling;
• exclusionary conduct.

For Indian synthetic-biology markets, relevant markets could potentially be defined around:

1. DNA synthesis;
2. genomic sequencing;
3. gene-editing technologies;
4. biological research tools;
5. synthetic-biology software;
6. engineered biological production;
7. specialized biological inputs.

The exact market definition would depend on substitutability, technology, geography and customer requirements.

23. Key Doctrinal Lessons From the Cases

The cases collectively demonstrate six important propositions.

1. Current sales are not everything

Illumina/PacBio shows the importance of nascent competition.

2. Innovation itself can be the competitive parameter

Genzyme/Novazyme illustrates the difficulty of analysing competition where firms compete through R&D pipelines.

3. Vertical concentration can create foreclosure risks

Illumina/GRAIL demonstrates how control over a critical upstream technology can create downstream competitive concerns.

4. Biological IP and innovation can justify merger scrutiny

Bayer/Monsanto and Dow/DuPont demonstrate the importance of innovation competition in biotechnology-intensive industries.

5. Sequential consolidation matters

ChemChina/Syngenta demonstrates why later mergers may need to be evaluated against an already consolidated industry.

6. Effective remedies may need to preserve the competitive capability itself

BMS/Celgene shows why a remedy may require transfer of IP, regulatory approvals and related assets rather than a superficial contractual undertaking.

24. Conclusion

Synthetic biology presents a distinctive competition-law problem because market power may arise from control over innovation infrastructure rather than merely from control over finished products.

The most significant concentration risks are likely to arise where one firm simultaneously controls:

technology + IP + biological data + research infrastructure + manufacturing + distribution.

Competition authorities therefore need to examine not only price and current market share, but also:

• innovation competition;
• nascent competitors;
• R&D pipelines;
• data advantages;
• intellectual-property portfolios;
• access to biological inputs;
• interoperability;
• vertical foreclosure;
• cumulative industry consolidation.

The Illumina/PacBio and Illumina/GRAIL matters are especially instructive for platform and sequencing concentration, while Genzyme/Novazyme, Dow/DuPont, Bayer/Monsanto and ChemChina/Syngenta demonstrate how competition law can address concentration in innovation-driven biological industries.

Thus, the central competition-law principle for synthetic biology is: